Indevus Pharmaceuticals ( IDEV) on Friday reported positive results for a late-stage trial of Nebido as a treatment of male hypogonadism.

The Lexington, Mass., biopharmaceutical company said the results from the phase III trial for the injectable testosterone therapy met all of its primary endpoints, which were related to hormone concentrations throughout dosing, and that the drug was well-tolerated.

The company, which bought the U.S. rights to Nebido from Bayer Schering Pharma AG in 2005, conducted the trial specifically to evaluate the once-every-three-month treatment under Food and Drug Administration guidelines for the approval of testosterone therapy products for the condition.

Indevus was down 3 cents, or 0.4%, to $7.29 in recent trading.

More from Stocks

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

Why Starbucks Latest Data Reveal Should Worry Investors

Why Starbucks Latest Data Reveal Should Worry Investors